Brainstorm Cell Therapeutics Inc (BCLI) stock has gained 12.83% over the past week and gets a Bullish rating from InvestorsObserver's Sentiment Indicator.
What is Stock Sentiment?
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.
As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.
InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.
For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What's Happening With BCLI Stock Today?
Brainstorm Cell Therapeutics Inc (BCLI) stock is trading at $16.36 as of 10:51 AM on Monday, Sep 28, a gain of $1.41, or 9.43% from the previous closing price of $14.95. The stock has traded between $14.96 and $16.47 so far today. Volume today is 283,345 compared to average volume of 355,807.
To see InvestorsObserver's Sentiment Score for Brainstorm Cell Therapeutics Inc click here.
More About Brainstorm Cell Therapeutics Inc
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
Click Here to get the full Stock Score Report on Brainstorm Cell Therapeutics Inc (BCLI) Stock.
